ABSI is trading 6.6% up today at $10.74, extending a rally driven by positive interim Phase 1 data for its ABS-201 hair loss and endometriosis therapy and strong demand for a $100 million underwritten stock offering. - The offering, priced at $7.41 per share and expected to close around June 25, 2026, is backed by Eli Lilly and other major institutional investors. - Proceeds are earmarked to fund the development of ABS-201, reinforcing market confidence in Absci’s AI-driven drug discovery platform.